Procaps Group, S.A. (PROC) Social Stream
PROCAPS GROUP SA (PROC) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering PROC.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
Price Target Last Issued May 16, 2023
The Trend in the Analyst Price Target
Over the past 17 months, PROC's average price target has gone down $6.
Over the past 48 weeks, PROC's average upside potential has been 63.46%.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
PROC Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
Over the past 48 weeks, PROC's average broker recommendation rating improved by 0.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- In terms of how PROCAPS GROUP SA fares relative to all US stocks, note that its number of analysts covering the stock is greater than just about none of of that group.
- PROCAPS GROUP SA's variance in analysts' estimates is lower than almost 100% of all US stocks.
- In the context of Healthcare stocks, PROCAPS GROUP SA's average analyst price target is greater than 57.04% of them.
- PROCAPS GROUP SA's upside potential (average analyst target price relative to current price) is greater than 163.16% of stocks in the small market cap category.
In the Pharmaceutical Products industry, COLL, AKBA, and EGRX are the three stocks most similar to PROCAPS GROUP SA regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Make investment decisions regarding PROC using the data that counts. Try POWR Ratings for free.